Recently, Grand Pharma (0512.HK) held the 2025 Interim Results Conference and Investor Open Day. During the event, the managements shared the company’s operational highlights from the first half of the year and its innovative strategic plan in nuclear medicine and critical care with investors. Multiple investors were also given an on-site tour of the nuclear medicine R&D and production base in Chengdu. It provided a tangible demonstration of the company’s closed-loop advantages across the entire nuclear medicine industry chain, underscoring Grand Pharma’s strategic plan for global innovation and R&D.
